ArticleFrontiers in neurology
Experimental verification and PK/PD modeling of selective drug absorption via acupoint administration in rabbit model of rheumatoid arthritis.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The administration of drugs at specific acupoints is a traditional practice in Chinese medicine, yet scientific evidence supporting its pharmacokinetic and pharmacodynamic (PK/PD) advantages remains limited. This study aimed to evaluate the transdermal absorption and therapeutic effects of miRNA55 when delivered via microneedles at different acupoints in a rabbit model of rheumatoid arthritis (RA). Methods: An RA model was established in New Zealand rabbits using ovalbumin-Freund's complete adjuvant emulsion. miRNA55 was encapsulated in cationic liposomes and combined with hyaluronic acid for microneedle preparation. Microneedles were applied at classical acupoint (ST36), atypical acupoints (GB34), and non-acupoint areas above the knee joint of the rabbits (avoiding ST35). Drug concentrations in the joint cavity fluid were assessed by microdialysis and enzyme-linked immunosorbent assay (ELISA). The encapsulation rate and Results: miRNA55 concentrations in the joint cavity were the highest in the ST36 group, followed by the GB34 and non-acupoint groups. This observation indicated that the degree of drug absorption. PK/PD modeling showed higher efficacy value for ST36 across all three cytokines. For IL-1β, Emax model for ST36 was Discussion: This study demonstrates that transdermal administration of miRNA55 via microneedle at specific acupoints enhances drug absorption and improves therapeutic outcomes in a rabbit model of RA. These findings support the traditional concept of acupoint specificity and offer a scientific basis for integrating acupoint-based drug delivery in modern RA treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.